T he proglucagon gene encodes multiple peptides related in amino acid sequence that are liberated in a tissue-specific manner in the brain, pancreas, and the enteroendocrine cells of the gastrointestinal tract. Glucagon, a 29 -amino acid peptide, is secreted from islet A cells and plays a key role in glucose homeostasis. In contrast, several peptides with distinct biological activities are secreted from enteroendocrine cells of the small and large bowel, including glicentin, oxyntomodulin, and 2 glucagon-like peptides (GLPs) designated GLP-1 and GLP-2. 1 Although glicentin and oxyntomodulin are cosecreted with GLP-1 and GLP-2 from the gut, much less is known about their biological activities in vivo. Glicentin stimulates intestinal growth in rodents, 2 and oxyntomodulin regulates gastric acid secretion and intestinal hexose transport, 3 but receptors for these peptides have not yet been defined and the physiologic relevance of glicentin and oxyntomodulin remains uncertain. In contrast, the biological activities of GLP-1 have been extensively characterized and include regulation of gastric emptying, stimulation of glucose-dependent insulin secretion, and inhibition of glucagon secretion, appetite, and food intake. 1 The multiple actions of GLP-1 result in lowering of blood glucose levels in rodents, normal human subjects, and patients with diabetes, raising the possibility that GLP-1 may be a useful adjunct for the treatment of patients with non-insulin-dependent diabetes.
More recent experiments have elucidated a role for GLP-2 as a regulator of intestinal mucosal growth. GLP-2 administered to rodents promotes increased crypt cell proliferation and decreases apoptosis, leading to increased villus height in the intestinal small bowel epithelium. 2, 4 Coinfusion of GLP-2 and parenteral intravenous nutrition in rats prevents the mucosal hypoplasia that occurs in the absence of enteral nutrition. 5 Furthermore, GLP-2 reduces the severity of experimental intestinal injury in rodents with ischemic intestinal injury or colitis, 6, 7 and enhances intestinal adaptation after major small bowel resection in the rat. 8 Together, these findings have stimulated considerable interest into the mechanism of GLP-2 action in vivo.
Both glucagon and GLP-1 are known to exert their actions through binding to distinct 7-transmembrane domain, G protein-linked receptors that are encoded by different genes. 9, 10 A separate GLP-2R has recently been isolated by expression cloning and shows significant amino acid homology to both the glucagon and GLP-1 receptors. 11 The GLP-2R specifically recognizes GLP-2, but not related members of the glucagon peptide superfamily. After GLP-2 binding to the transfected receptor, adenosine 3Ј,5Ј-cyclic monophosphate levels are increased, 11, 12 consistent with findings from studies of related members of the glucagon/GLP-1R family.
Although RNase protection assays showed GLP-2R expression in the rat gastrointestinal tract, 11 little is known about intestinal GLP-2R expression. Whether the GLP-2R gene gives rise to a single RNA transcript, as is the case for the glucagon receptor, or multiple RNAs, as shown for the GLP-1R, 10 remains unknown. Furthermore, the multiple actions of GLP-2 on proliferation, apoptosis, gastric emptying, and hexose transport 13 raise important questions as to whether these diverse effects are direct or indirect; however, the cell types that express the GLP-2R in the gastrointestinal tract have not yet been identified. To gain further insight into the mechanism of GLP-2 action, we have studied GLP-2R expression in rodent and human tissues using a combination of reverse-transcription polymerase chain reaction (RT-PCR), Northern blotting, and immunocytochemistry.
Materials and Methods

Animals
Mice transgenic for the rat GLP-2R complementary DNA (cDNA) under the control of the intestinal fatty acidbinding protein (FABP) promoter 14 were generated and propagated in accordance with the guidelines of the Toronto General Hospital Animal Care Committee. These mice were generated to assess the effects on enterocyte biology of targeted expression of the GLP-2R to a localized intestinal epithelial compartment. 14 Because FABP-GLP-2R mice express high levels of the translated rat GLP-2R in the murine small bowel epithelium, FABP-GLP-2R mice were used as a positive control for GLP-2R immunohistochemistry experiments. Sprague-Dawley rats and CD1 mice were obtained from Charles River Canada (Toronto, Ontario).
Tissues and Cell Lines
Histologic sections of human stomach, small intestine, and large intestine were obtained from autopsy material from the Department of Pathology, Mount Sinai Hospital, University of Toronto, Canada. Carcinoid tumors (locally invasive endocrine tumors from the gastrointestinal tract) were also Intestinal cell lines IEC6, IEC14, IEC17, IEC18,  IEC19 , and IEC20, as well as CaCo2, Colo201, Colo205, Colo320, SW620, SW1116, and HT29 cells were a generous gift from Dr. D. Gauci (Ontario Cancer Institute, Toronto, Ontario). Rat pancreatic lines RIN14B, RINSF, and RINM and cell lines IMR32, SK-N-MC, PC12, and T84 were purchased from American Type Culture Collection. The GLUTag and STC-1 murine intestinal endocrine cell lines were from the Drucker Laboratory (Toronto, Canada). 15, 16 Cell Culture IEC cell lines were maintained in ␣-minimal essential medium (MEM) supplemented with 10% fetal bovine serum (FBS), 1% glucose, and 1% L-glutamine and harvested at 60%-70% confluency, 80%-90% confluency, and 100% confluency. Adenocarcinoma cell lines CaCo2, Colo201, Colo205, Colo320, HT29, SW620, SW1116, and HT29 were grown in ␣-MEM supplemented with 10% FBS and 1% glutamine. T84 cells were grown in 50% Ham's F12 media, 50% Dulbecco's modified Eagle medium supplemented with 10% FBS, and 1% glutamine. Rat pancreatic cells were maintained in RPMI 1640 media supplemented with 10% FBS and neuroblastoma cells in Dulbecco's modified Eagle medium/F12 media supplemented with 10% FBS. Adenocarcinoma cell lines CaCo2, HT29, SW620, and Colo205 were differentiated either spontaneously over several days (CaCo2), in the presence of 2 mmol/L sodium butyrate (Colo205 and SW620) or 5 mmol/L sodium butyrate (HT29). GLUTag and STC-1 cells were propagated as previously described. 15, 16 
RNA Isolation and Northern Blot Analysis
Total RNA was isolated from rat and mouse tissues by the guanidinium thiocyanate method. 17 PolyA ϩ RNA was isolated using the polyATract System (Promega, Madison, WI) and quantified by fluorometry. For Northern blotting, 2 g of polyA ϩ RNA was electrophoresed in a 1% agarose-formaldehyde gel, transferred to a Nytran membrane (Schleicher & Schuell, Keene, NH), and UV cross-linked using a Bio-Rad UV chamber (Bio-Rad Laboratories, Richmond, CA). After prehybridization, membranes were hybridized with a 32 Plabeled cDNA probe overnight at 42°C in 40% formamidecontaining buffer. 32 P-labeled cDNA probes were generated by random priming from rat GLP-2R cDNA, 11 rat GLP-1R, 18 rat GIP receptor, 19 mouse glucagon receptor, 18 and rat glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 20 generated by RT-PCR (as indicated later). Blots were washed at high stringency (0.1ϫ standard saline citrate [SSC] plus 0.1% sodium dodecyl sulfate [SDS], 65°C) and exposed to Kodak X-Omat film (Eastman Kodak, Rochester, NY) at Ϫ70°C with intensifying screens for the indicated time periods. Before rehybridization with subsequent probes, membranes were stripped at 80°C in 0.01ϫ SSC plus 0.5% SDS.
Semiquantitative RT-PCR
For first-strand cDNA synthesis, 5 g of DNase I-treated total RNA from rat tissues underwent reverse transcription at 42°C for 50 minutes using random hexamers and SuperScript II (Life Technologies, Gaithersburg, MD). Aliquots of the first-strand reactions (1/20 vol) were used as templates for PCR using Taq polymerase (Life Technologies). PCR was performed over a range of cycles spanning the exponential phase of amplification kinetics, and linearity was shown for relative cDNA input across 2 orders of magnitude. Primer pairs selected for PCR were: rat GLP-2 R 5Ј-TTGT-GAACGGGCGCCAGGAGA-3Ј and 5Ј-GATCTCACTCT-CTTCCAGAATCTC-3Ј; rat GAPDH 5Ј-TCCACCACCCT-GTTGCTGTAG-3Ј and 5Ј-GACCACAGTCCATGACAT-CACT-3Ј. Amplification of rat GLP-2R cDNA was performed at an annealing temperature of 65°C for 26 cycles, resulting in the generation of a 1672-base pair (bp) product spanning the entire GLP-2R open reading frame. For human GLP-2R RT-PCR, 0.15 mol/L primers HWBR-F1 (5Ј-CTTATTCCTT-TCCTGGC-3Ј) and HWBR-R4 (5Ј-GACAGGTAGGA-CATCCACC-3Ј) were used. Samples were denatured at 94°C for 2 minutes and submitted to 30 cycles of PCR (94°C for 40 seconds, 58°C for 40 seconds, and 72°C for 30 seconds) with an additional extension at 72°C for 8 minutes. Positive controls for human GLP-2R RT-PCR consisted of COS-7 or baby hamster kidney (BHK) cells transiently transfected with the human GLP-2R. GAPDH cDNA amplification was performed at an annealing temperature of 60°C for 24 cycles, resulting in the generation of a 452-bp product. GAPDH cDNA amplification was used as an internal control for the efficiency of first-strand cDNA synthesis. The specificity of each amplification reaction was monitored by control reactions in which amplification was performed on samples in which the RT was omitted from the RT reaction mixture (RTϪ).
PCR products were analyzed by agarose gel electrophoresis followed by ethidium bromide staining and quantification by computer imaging (GAPDH cDNA) or by Southern blotting (GLP-2R cDNA). RT-PCR Southern blots were hybridized with a 32 P-labeled GLP-2R probe using nucleotide sequences internal to the PCR primers to verify the authenticity of the PCR product. Blots were washed at 65°C in 0.1ϫ SSC, 0.1% SDS, and exposed against a phosphorimaging screen for quantification on a PhosphorImager (Molecular Dynamics, Sunnyvale, CA).
Antisera and immunocytochemistry. GLP-2R antisera were raised in rabbits against a GST-GLP-2R fusion protein generated in Escherichia coli. The fusion protein contained amino acids 457-550 of the GLP-2R, and was purified from bacterial extracts by GST column chromatography before immunization. Antisera were affinity-column purified against the original immunogen before use in immunocytochemistry. Tissues obtained from rodents or from human patients at autopsy were fixed overnight in buffered formalin, embedded in paraffin, and used for immunocytochemical analysis, as described previously. 21 GLP-2R antisera were used at a dilution of 1:800 to 1:1600. Nonspecific positivity was assessed by analysis of staining with preimmune sera, by omission of primary antisera, and by analysis of wild-type BHK cells and BHK cells transfected with the rat or human GLP-2R. Histologic sections from the small intestine of an FABP-promoter rat GLP-2R transgenic mouse 14 were also used as positive controls to verify the presence of antisera that recognized the rat GLP-2R in tissue sections in vivo.
Antisera recognizing endocrine cell secretory products were used as previously described. 22 For analysis of the relative numbers of GLP-2R-immunopositive endocrine cells in different regions of the gut, several hundred serotonin-and chromogranin-immunopositive cells were examined and compared with the number of GLP-2R-immunopositive cells in adjacent serial sections. Histologic sections from different regions of the human gastrointestinal tract were analyzed using the avidin-biotin-peroxidase technique and primary antisera directed against cholecystokinin (CCK) (1:2000; Serotec, Oxford, England), chromogranin (1:1000; Biomeda, Foster City, CA), gastrin (1:100; Zymed, San Francisco, CA), GIP (1:400; Peninsula, Belmont, CA), GLP-1 (1:2500; Drucker Laboratory), PYY (1:2000; Peninsula), secretin (1:100; Biogenex, San Ramon, CA), serotonin (1:50; Dako, Carpinteria, CA), and somatostatin (1:1000; Dako).
Western Blot Analysis
Whole cell-membrane extracts from STC-1 cells, GLUTag cells, BHK cells transfected with the rat GLP-2R, and 293 EBNA cells expressing a transfected human GLP-2R 11 were resolved by SDS-polyacrylamide gel electrophoresis (PAGE) under reducing conditions, transferred to nitrocellulose membranes, and analyzed by Western blotting, as described previously. 23 Loading and transfer conditions were assessed by staining of the gel with Coomassie or the membrane with Ponceau S. Membranes were incubated with preimmune or GLP-2R-immune antisera overnight at a dilution of 1:1000, and proteins were visualized by using a secondary antibody conjugated to horseradish peroxidase, detected by enhanced chemiluminescence (Amersham Pharmacia Biotech, Toronto, Ontario). 
Results
Multiple GLP-1R RNA transcripts have been detected using Northern blotting and GLP-1R-specific cDNA probes 10, 24 ; however, whether the GLP-2R gene also gives rise to multiple transcripts is not currently known. Because messenger RNA (mRNA) transcripts for related members of the glucagon receptor superfamily potentially cross-hybridize with GLP-2R probes, we first ascertained the specificity of Northern blotting for detection of GLP-2R mRNA transcripts. RNA isolated from rat jejunum, lung, skeletal muscle, and the liver was hybridized in separate experiments with cDNA probes for the GLP-2R, GLP-1R, glucagon receptor, and GIP receptor (Figure 1) . A single major GLP-2R-mRNA transcript of ϳ5.8 kb was detected in polyA ϩ RNA from rat jejunum, but no GLP-2R-RNA transcripts were detected in polyA ϩ RNA from the rat lung, muscle, or liver. In contrast, 2 major GLP-1R-mRNA transcripts were detected in the rat lung that migrated more rapidly than the larger jejunal GLP-2R mRNA (Figure 1) . However, no GLP-1R-mRNA transcripts were detected in the rat jejunum, muscle, or liver, consistent with results from previous Northern blotting experiments. 10 Similarly, a single glucagon receptormRNA transcript was detected in the rat liver, but not in RNA from jejunum, lung, or muscle (Figure 1) . A single GIP receptor-mRNA transcript was detected in polyA ϩ RNA from jejunum, ϳ4.0 kb in size, clearly smaller in size than the jejunal GLP-2R-mRNA transcript. Together, these findings establish the specificity of Northern blotting for the detection of GLP-2R-mRNA transcripts and show that transcription of the GLP-2R gene gives rise to a single mRNA transcript.
The results of several studies have established that GLP-2 promotes mucosal growth in both the small and large bowel, and inhibits gastric emptying and mealstimulated gastric acid secretion. [25] [26] [27] We initially used Northern blotting to analyze the distribution and relative abundance of GLP-2R-RNA transcripts along the gastrointestinal tract. GLP-2R-mRNA transcripts were not detected in the esophagus, but were observed in more distal regions of the gastrointestinal tract, with relatively higher levels of expression observed in the small and large bowel than in the stomach (Figure 2A ). In contrast, although a GLP-2R cDNA was cloned from a hypothalamic cDNA library, 11 we did not detect GLP-2R-mRNA transcripts by Northern blotting analysis in polyA ϩ RNA from the hypothalamus, cortex, cerebellum, or brain stem (Figure 2A) . No GLP-2R-mRNA transcripts were detected by Northern blotting in a range of peripheral tissues, including the liver, pancreas, kidney, gonads, and skeletal muscle tissue ( Figure 2B) .
The inability to detect GLP-2R-mRNA transcripts by Northern blotting in tissues such as the hypothalamus prompted us to use more sensitive techniques such as a RT-PCR assay for detection of low-abundance mRNA transcripts. We first analyzed GLP-2R-mRNA transcripts in total RNA from rat jejunum over a range of PCR cycles to establish conditions for semiquantitative detection of gene expression. A linear relationship was obtained between PCR product and cycle number between 22-30 cycles ( Figure 3A) , hence, 26 cycles were chosen for further RT-PCR experiments. To ascertain the use of this assay for detection of GLP-2R-mRNA transcripts in the gastrointestinal tract and brain, we analyzed GLP-2R expression over a range of cDNA inputs by using cDNA from rat jejunum and brain stem. GLP-2R-mRNA transcripts were detected, in a linear semiquantitative manner, over a broad range of input (cDNAs) in both tissues, establishing the sensitivity of the RT-PCR assay ( Figure 3B) . Furthermore, the relative abundance of GLP-2R expression by RT-PCR was at least 20 -30-fold greater in the jejunum than brain stem, consistent with the results from Northern blotting experiments.
We next examined GLP-2R expression by RT-PCR using RNA from multiple tissues. GLP-2R-mRNA transcripts were detected by RT-PCR ( Figure 3C ) in RNA from the hypothalamus, brain stem, and lung. In contrast, GLP-2R-mRNA transcripts were not detected by RT-PCR in most of the tissues examined, including the heart, muscle, and kidney.
To localize the specific cell types that express the GLP-2R, we generated antisera directed against amino acids 457-550 in the carboxy-terminal region of the rat GLP-2R. Several antisera gave positive staining of GLP-2R-transfected cell lines, and 1 immunopurified antiserum was subsequently used for detection of GLP-2R immunopositivity in histologic sections from rodent and human tissues. To verify that immunopositivity in immunocytochemical analyses was consistent with the detection of a GLP-2R protein, we performed Western blot analysis of GLP-2R-transfected cell lines ( Figure 4A in the absence of posttranslational modifications, after cleavage of a putative signal peptide, is ϳ56.2 kilodaltons. A single major band of ϳ72 kilodaltons was recognized in EBNA cells transfected with the human GLP-2R. 11 A similarly migrating 72-kilodalton band and a smaller ϳ60-kilodalton band were detected in extracts from BHK cells transfected with the rat GLP-2R. A minor band of ϳ50 kilodaltons, consistent with a possible degradation product, was also observed in BHK cell extracts. In contrast, no GLP-2R-immunoreactive proteins were detected in control BHK cell extracts ( Figure 4A, lane 1) . Similarly, GLP-2R-immunoreactive proteins were not detected in transfected cells when using preimmune sera (data not shown).
To ascertain whether the GLP-2R antisera identified GLP-2R-immunopositive cells in histologic tissue sections, we first analyzed histologic sections from FABP-GLP-2R transgenic mice as a positive control. These mice overexpress the rat GLP-2R under the control of the intestinal FABP. 14 No GLP-2R immunopositivity was detected in enterocytes from wild-type nontransgenic mouse intestine ( Figure 4B ). In contrast, FABP-GLP-2R transgenic murine enterocytes were strongly immunopositive with the GLP-2R antisera ( Figure 4C ) and the GLP-2R immunopositivity was eliminated after preincubation of the GLP-2R antisera with recombinant GLP-2R immunogen ( Figure 4D ).
Because the GLP-2R is a member of the glucagon/ secretin receptor superfamily that exhibits regions of amino acid homology in conserved subdomains, we next assessed whether the GLP-2R antisera cross-reacts with either of the structurally related GLP-1R or glucagon receptor. No immunopositive pancreatic islet or exocrine cells or hepatocytes were detected in sections of rat or human pancreas and liver (data not shown), consistent with the lack of detectable GLP-2R-mRNA transcripts in these tissues (Figure 2) . Furthermore, the GLP-2R antisera did not recognize the GLP-1R in extracts from cells transfected with the GLP-1R in vitro (not shown). Because islets and liver express the GLP-1 and glucagon receptors, these findings show that the GLP-2R antisera specifically detect the GLP-2R, but not the glucagon or GLP-1R in histologic tissue sections.
To localize the specific intestinal cell types that express the GLP-2R, we studied tissue sections from different regions of the human gut. Analysis of multiple histologic sections showed occasional GLP-2R-immunopositive cells in the epithelium of the stomach and both the small and large intestine ( Figure 5A-H) . The GLP-2R-immunopositive cells were rare in all regions of the gastrointestinal tract, ranging from 0 to 2 detectable cells in most low-power histologic sections of the stomach, and both the small and large intestine. In the stomach, the majority of GLP-2R-positive cells were localized to the lower portion of the pyloric antrum. Occasional, rare low-power fields from the human colon had up to 5-10 GLP-2R-positive cells. In the small bowel, GLP-2R-positive cells were seen both at the base of the villous epithelium, and immunopositive cells could also be detected at various locations along the length of the entire crypt-to-villus axis.
The abundance, appearance, and location of the GLP-2R-positive cells within the epithelium suggested that GLP-2R was expressed in intestinal endocrine cells. Consistent with this hypothesis, analysis of serial sections stained with antisera against either the GLP-2R or gut endocrine cell markers showed that GLP-2R-immunopositive cells in the stomach and both the small and large intestine also contained chromogranin immunopositivity ( Figure 6A-D) . Similarly, endocrine cells in the duodenum and large intestine were identified that contained both GLP-2R and serotonin immunopositivity ( Figure 6E-H) .
Although the majority of GLP-2R-positive cells contained chromogranin immunoreactivity, the majority (Ͼ80%) of the chromogranin-positive cells in the stomach and duodenum did not contain GLP-2R immunopositivity. Similarly, Ͼ70% of chromogranin-positive cells in the small bowel were GLP-2R immunonegative. In contrast, ϳ50% of all chromogranin-positive cells in the colon contained GLP-2R immunopositivity. In the colon, there were twice as many serotonin-positive cells as GLP-2R-positive cells, but most GLP-2R-positive cells also contained serotonin immunoreactivity.
In contrast to the localization of GLP-2R immunopositivity in endocrine cells, GLP-2R-immunopositive cells were not detected in nonendocrine gastric cell lineages or in enterocytes of the small bowel villous epithelium ( Figure 5) . Similarly, serosa and muscle layers in the stomach and both the small and large bowel did not contain GLP-2R-immunopositive cells ( Figure 5 and data not shown). To determine the hormonal phenotype of the subset of enteroendocrine cells that expressed GLP-2R, we analyzed adjacent serial sections from the human stomach, and both the small and large intestine, for GLP-2R and hormone immunopositivity. The majority of all endocrine cell populations identified with different antisera in the stomach and both the small and large intestine did not contain GLP-2R immunopositivity. The majority of gastrin-positive cells in the stomach, and secretin-and somatostatin-positive cells in the small bowel, were GLP-2R immunonegative. An occasional duodenal endocrine cell exhibited both GIP and GLP-2R positivity, but most GIP-positive K cells did not contain GLP-2R immunoreactivity (Figure 6M-P) . Several cells were identified in the ileum that contained both PYY and GLP-2R immunoreactivity ( Figure 6K and L) . Intriguingly, occasional endocrine cells that produce GLP-1 and GLP-2 were also GLP-2R immunopositive in the small bowel ( Figure  6I and J) . In contrast to the findings in the small bowel, and despite the relative abundance of GLP-1-immunopositive cells in the large bowel, we did not observe enteroendocrine cells in the large bowel that contained both GLP-1 and GLP-2R immunopositivity. Similarly, no somatostatin-or CCK-immunopositive cells were detected that also contained GLP-2R immunopositivity in either the small or large bowel.
After the localization of GLP-2R immunopositivity to normal gut endocrine cells, we hypothesized that human carcinoid tumors arising from intestinal endocrine cells might also exhibit GLP-2R immunopositivity. Although the majority of cells in the 4 human intestinal carcinoid tumors studied did not contain GLP-2R immunopositivity, small focal areas of GLP-2R positivity were observed in 3 of 4 tumors examined ( Figure 7A and B). Consistent with the restriction of GLP-2R expression to gut endocrine lineages, we did not detect GLP-2R mRNA transcripts by RT-PCR in IEC6, IEC14, IEC17, IEC18, IEC19, IEC20, CaCo-2, Colo201, Colo205, Colo320, SW480, SW48, DLD-1, SW620, SW1116, T84, HCT-81, and HT-29 cell lines from the small and large intestine. Similarly, no GLP-2R-mRNA transcripts were detected in central nervous system-derived neuroblastoma cells (IMR32, SK-N-MC, CHP-126, NMB/N7), pheochromocytoma cells (PC12), or in pancreatic islet cell lines (RIN14B, RIN5F, and RINM cells). Furthermore, no GLP-2R-mRNA transcripts or GLP-2R-immunoreactive protein were detected in RNA or cell extracts from the STC-1 or GLUTag gut murine endocrine cell lines (Figure 7C and D) .
Discussion
Our studies show that GLP-2R expression, as assessed by a combination of Northern blotting, RT-PCR, and immunocytochemistry, is predominantly restricted to the gastrointestinal tract and brain. The observation that GLP-2R-mRNA transcripts are expressed at low levels in the gastrointestinal tract, and detectable only by sensitive techniques such as Northern blotting with polyA ϩ RNA, RNAse protection assays, or RT-PCR, is in keeping with previous efforts that failed to detect GLP-2 binding in the gastrointestinal epithelium when various experimental approaches were used. 28 Indeed, our studies clearly show that GLP-2R-immunopositive cells are not abundant in representative histologic sections of the small and large bowel, consistent with the low levels of GLP-2R-mRNA transcripts detected by Northern and RT-PCR analyses. In contrast to the more widely expressed GLP-1 and glucagon receptors, 18,29 the comparatively restricted pattern of GLP-2R expression suggests that the direct actions of GLP-2 are likely to be considerably more localized, predominantly to the gastrointestinal tract.
The localization of GLP-2R immunopositivity to endocrine cells of the stomach and both the small and large intestine was somewhat unexpected. These findings suggest that at least some of the effects of GLP-2 on crypt cell proliferation, apoptosis, intestinal hexose transport, and both gastric motility and acid secretion are indirect, and likely mediated by as yet unidentified factors released from GLP-2R-positive enteroendocrine cells in vivo. The localization of the majority of GLP-2-producing endocrine cells to the distal small bowel and colon suggests that GLP-2 actions on endocrine cells in the stomach and proximal jejunum may be mediated via circulating GLP-2 in an endocrine manner. Nevertheless, it remains possible that locally derived GLP-2 also acts on adjacent endocrine cells in a paracrine manner ( Figure  8 ). The lack of GLP-2R immunopositivity in small bowel enterocytes or in colonic mucosal epithelial cells is in keeping with our inability to detect GLP-2R expression in immortalized intestinal cell lines derived from the small bowel or from large bowel tumors. In contrast, consistent with the findings of GLP-2R expression in gastrointestinal endocrine cells, rare scattered groups of GLP-2R-positive cells were detected in several human gastrointestinal carcinoid tumors.
What are the implications of GLP-2R expression in enteroendocrine cells of the gastrointestinal tract for understanding GLP-2 action? The gut contains a complex population of endocrine cells that exhibits regionspecific differences in abundance and hormonal pheno- Many neuroendocrine peptides exhibit trophic activity in the gastrointestinal tract, including gastrin, neurotensin, gastrin-releasing peptide, and peptide YY. 30, 31 Furthermore, molecules with potent intestinotrophic activity such as TGF-␣ and fibroblast growth factors have been localized to endocrine cells in the human gastrointestinal tract. 32, 33 Hence, it seems likely that enteroendocrine-derived GLP-2 promotes gut growth and repair by stimulating the liberation of 1 or more trophic molecules from specialized endocrine cells that express the GLP-2R. The identity of the enteroendocrine-derived downstream mediators of GLP-2 action (Figure 8 ) remains unknown and is clearly an important issue for future investigation.
Intriguingly, enteroendocrine cell populations have been noted to be increased in several human intestinal diseases including celiac disease, Hirschprung's disease, and inflammatory bowel disease. 34 -38 Furthermore, in the setting of intestinal inflammation, intestinal endocrine cells may express molecules such as the trefoil factor pS2 that potentially exerts protective effects on adjacent intestinal epithelium. 38 Hence, some of the effects of exogenous GLP-2 in experimental models of murine inflammatory bowel disease 7, 39 and in enhancing barrier function in normal mice 40 may be caused by the liberation of enteroendocrine-derived molecules that exert diverse actions, including stimulation of mucosal repair mechanisms and protection from further epithelial injury in vivo.
Although the biology of intestinal endocrine cells remains poorly understood, increasing evidence suggests that some enteroendocrine cells are regulated by circulating or locally derived hormones through expression of G protein-linked peptide-hormone receptors. For example, GLP-1 release from enteroendocrine cells is stimulated by gastrin-releasing peptide and GIP in both primary intestinal cell cultures and in animals in vivo. [41] [42] [43] Furthermore, the parathyroid hormone 2 receptor, NPY/ PYY Y-1 receptor, and somatostatin-2A receptor have been localized to gastrointestinal endocrine cells in vivo. 44 -46 These findings, together with our results of GLP-2R localization on gut endocrine cells, imply the existence of a complex peptidergic communication system for transduction of regulatory signals to and from specialized endocrine cells of the gastrointestinal tract.
What are the implications of the molecular and cellular biology of GLP-2R expression for understanding GLP-2 action in vivo? The single major GLP-2R-mRNA transcript detected by Northern analysis, taken together with the single RT-PCR product obtained with primers spanning the entire GLP-2R coding sequence, implies that alternative exon splicing to generate multiple receptor isoforms with differing biological activities is unlikely to be a feature of GLP-2R biology. Given the highly limited cellular expression of the GLP-2R in enteroendocrine cells of the intestinal epithelium, it is perhaps not surprising that gastrointestinal cell lines that express the endogenous GLP- 2R have not yet been reported. Further characterization of the endocrine cell populations that express the GLP-2R, and identification of the growth factors and peptides secreted by the GLP-2-stimulated GLP-2R-immunopositive enteroendocrine cells, is clearly an important next step to further advance our understanding of the biology of GLP-2 action.
